[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544656":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"IRCCS Ospedale San Raffaele","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1","EXPERIMENTAL","Substrate-based DEEP Mapping",[13],"Procedure: DEEP mapping",{"label":15,"type":10,"description":16,"interventionNames":17},"group 2","VT Activation Mapping",[18],"Procedure: Activation Mapping",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","DEEP mapping","The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.\n\nDevice use for mapping and ablation procedure:\n\nFlexAbility\u002FTactiflex\u002FTactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Activation Mapping","VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification\n\nDevice use for mapping and ablation procedure:\n\nFlexAbility\u002FTactiflex\u002FTactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Andrea Radinovic, MD","CONTACT","+390226436316","radinovic.andrea@hsr.it",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Anna Montagna, PhD","+390226437489","montagna.anna@hsr.it",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"San Raffaele Hospital","RECRUITING","Milan","Lombardy","20132","Italy","IT",{"type":50,"coordinates":51},"Point",[52,53],9.18951,45.46427,{"lat":53,"lon":52},[56,58],{"name":57,"role":33,"phone":25,"phoneExt":25,"email":25},"Paolo Della Bella, MD",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Dr. Paolo Della Bella","Medical Doctor","100544656","deep-substrate-mapping-versus-activation-mapping-for-vt-100544656",false,"NCT06371729","DEEP Substrate Mapping Versus Activation Mapping for VT","Substrate-based DEEP Mapping Versus Activation Mapping: A Prospective Randomized Multicenter Study","Inclusion Criteria:\n\n* Patients with an implanted ICD (all brands)\n* Patients with the indication for Ventricular Tachycardia Ablation (both first and redo procedures), supported by EnSite 3D mapping system, for the following disease aetiologies: previous MI, myocarditis, arrhythmogenic right\u002Fleft ventricular dysplasia\n* Age: 18 years or more.\n* A participant is willing and able to give informed consent for participation in the trial and is available to respect the assessments described in the protocol and informed consent form.\n\nExclusion Criteria:\n\n* Contraindication to anticoagulants.\n* Presence of thrombi.\n* Presence of Mitral and Aortic prosthetic valve.\n* Recent (less than 3 months) myocardial infarction, unstable angina, or Coronary Artery Bypass.\n* Ventricular Tachycardia caused by reversible pathology.\n* Life expectancy less than 1 year, according to the investigator.\n* Contraindications to the use of ablation\u002Fdiagnostic catheters or to cardiac catheterization.\n* Female participant who is pregnant, lactating, or planning pregnancy during the course of the trial.","ALL","18 Years",{"count":73,"type":74},222,"ESTIMATED","INTERVENTIONAL",[77],"NA","Substrate-based DEEP mapping and activation mapping are two of the main techniques used for guiding ventricular tachycardia (VT) ablation. There is no data comparing directly the extent of applicability, procedural results, and the long-term outcomes between the two mapping strategies.This randomized clinical trial aims to test whether activation mapping is superior to DEEP mapping to reduce ventricular tachycardia recurrence.\n\nThe primary endpoint of the study is to compare recurrence-free survival rate of ventricular tachycardia at 12 months and procedural feasibility of substrate-based DEEP mapping versus activation mapping for VT ablation.",[80],"Ventricular Tachycardia",[82,83],"DEEP substrate mapping","Activation mapping","2026-03-24",{"date":86,"type":87},"2026-03-27","ACTUAL",{"date":89,"type":87},"2024-06-13",{"date":91,"type":74},"2027-06",{"name":5,"class":6},1]